Cash-pay derm and aesthetics: the practice model reshaping dermatology

May 6, 2026 · Pouyan Golshani, MD, Interventional Radiologist

Cash-pay aesthetics is the highest-margin practice model in dermatology. Here’s the structure, the regulatory landscape, and the operating economics. This isn’t just about Botox and fillers; it’s a fundamental shift in the business of medicine, moving from a volume-based, third-party-payer system to a value-based, direct-to-consumer model. For physician-owners, this transition unlocks incredible financial upside but also introduces a new level of financial complexity. Success is no longer just about clinical skill; it’s about mastering the tax code, understanding corporate finance, and structuring your practice for maximum enterprise value. Most of us learn these lessons the hard way—by overpaying in taxes or leaving millions on the table during a sale. This article is designed to be the primer I wish I had, covering the key financial levers that separate a good cash-pay practice from a great one. For a broader look at the clinical and operational side, you can explore our full suite of dermatology free tools and resources.

Private Equity Buyout Tax Structuring: The Difference Between Capital Gains and Ordinary Income

Dermatology practices, especially those with a strong aesthetics component, are prime targets for private equity (PE) roll-ups. When that letter of intent arrives, the headline number—the purchase price—is seductive. But the real number, the one that hits your bank account, is determined by a single, critical line item: the deal structure. The difference between an “asset sale” and a “stock sale” can mean a seven-figure swing in your after-tax proceeds.

Here’s the breakdown:

Asset Sale: This is the structure PE firms almost always propose first because it benefits them. The buyer purchases the individual assets of your practice—equipment, patient lists, goodwill, accounts receivable—but not the legal entity (your S-Corp or LLC) itself. For the buyer, this is great; they get a “step-up in basis” on the assets, allowing them to depreciate them again from the purchase price, creating a massive tax shield for themselves. For you, the seller, it’s often a tax disaster. While the goodwill portion is taxed at favorable long-term capital gains rates, a significant chunk of the sale price is allocated to assets that trigger ordinary income tax. This includes collected accounts receivable and, crucially, “depreciation recapture” on your equipment. All the depreciation you’ve claimed over the years is recaptured and taxed as ordinary income, at rates potentially pushing 40%.
Stock Sale: In this structure, the buyer purchases the stock of your corporation. You sell your shares, and the entire gain (purchase price minus your stock basis) is typically treated as a long-term capital gain, taxed at a much lower rate (currently 20% plus net investment income tax). This is vastly superior for the physician-owner.

When I look at a term sheet, this is the first thing I check. The negotiation isn’t just about the price; it’s about the structure. A PE firm might offer a slightly higher price for an asset sale, knowing they’ll make up the difference (and then some) on their own tax savings. The planning trap is focusing solely on the headline number. You must model the after-tax proceeds of both structures. Pushing for a stock sale, or a hybrid structure that minimizes ordinary income allocation, is one of the highest-value negotiations you will have in your career.

Equity Rollover Deal Mechanics: Deferring Tax and Retaining Upside

In most PE buyouts, the deal isn’t 100% cash. A common structure involves taking some chips off the table while keeping skin in the game through an “equity rollover.” Instead of selling 100% of your practice for cash, you might sell 70-80% for cash and “roll” the remaining 20-30% of your ownership into equity of the new, larger parent company (“NewCo”) that the PE firm has created.

The mechanics are powerful. The cash portion of the sale is a taxable event, subject to the capital gains or ordinary income treatment we just discussed. The rollover portion, however, is generally structured as a tax-deferred exchange under Internal Revenue Code §351 or §721. This means you do not pay taxes on the value of the rolled equity until a future “second bite of the apple”—when the PE firm sells the entire platform to another buyer, typically 3-7 years down the line.

Here’s how to think about it:

Tax Deferral: You’re deferring a significant tax liability, allowing that capital to remain invested and (hopefully) grow within the larger, professionally managed entity.
Retained Upside: You are now a minority owner in a much larger platform. If the PE firm successfully executes its growth strategy—acquiring more practices, improving operations, and increasing EBITDA—the value of your rollover equity could multiply significantly, leading to a second liquidity event that dwarfs your initial cash payout.
Risk Management: The percentage you roll over is a key negotiation point. A higher rollover (e.g., 40%) signals confidence and can sometimes command a better valuation, but it also ties more of your net worth to the PE firm’s performance. A lower rollover (e.g., 20%) de-risks your personal finances by putting more cash in your pocket today.

The trap here is twofold. First, failing to perform due diligence on the PE firm itself. What is their track record in dermatology? Who are the operators? Second, not understanding the valuation and terms of the NewCo equity you’re receiving. Is it preferred or common stock? What are your rights as a minority shareholder? This isn’t just a financial transaction; you’re choosing a new business partner. The quality of that partner determines whether your “second bite” is a feast or a famine.

R&D Tax Credits: Your Custom Formulations Are a Tax Asset

Most physicians think of R&D tax credits as something for tech companies or pharmaceutical giants. Most are wrong. Many cash-pay dermatology and aesthetics practices are performing qualifying research and development activities every single day and leaving tens of thousands of dollars on the table by not claiming the credit.

The R&D tax credit, governed by IRC §41, is designed to incentivize businesses to develop new or improved products, processes, or software. The key is that the activity doesn’t have to be a Nobel-prize-winning breakthrough. It simply needs to involve a process of experimentation to eliminate technical uncertainty.

Consider these common activities in a sophisticated derm practice:

Developing Proprietary Skincare Compounds: Are you working with a compounding pharmacy to create a custom-formulated retinol, vitamin C serum, or post-procedure healing cream? The process of testing different concentrations, stability, and patient outcomes is a qualifying R&D activity. The costs of supplies and staff time dedicated to this are qualified research expenses (QREs).
Creating New Clinical Protocols: Are you systematically testing new combinations of laser treatments, energy-based devices, and injectables to optimize results for specific conditions like rosacea or melasma? Documenting these protocols, tracking outcomes, and refining the process qualifies.
Building Internal Software: Did you develop a custom module for your EMR to better track aesthetic patient outcomes with photo documentation? Or perhaps a tool to manage your subscription-based facial membership program? The internal software development costs can qualify.

The how-to sequence involves working with a specialized accounting firm to conduct an R&D credit study. They will help you identify qualifying activities and document the associated expenses (wages for the people involved, supplies used, and contract research costs). The credit is a direct, dollar-for-dollar reduction of your income tax liability. The trap is assuming you don’t qualify. Most physicians are so focused on the clinical side that they overlook the fact that their daily work of innovation has a direct, quantifiable tax benefit.

Practice Valuation Drivers and EBITDA Multiples

Whether you plan to sell to private equity or simply want to build a valuable asset, you need to understand how your practice is valued. In the world of PE, the language is “EBITDA multiples.” EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization, and it’s a proxy for the practice’s operating cash flow. A buyer will value your practice by applying a multiple to this number (e.g., 8x EBITDA).

A practice with $1M in EBITDA might sell for $8M, while another practice with the same EBITDA might command a 10x multiple and sell for $10M. What drives that multiple higher? It’s not just about profitability; it’s about the *quality* and *predictability* of that profit.

Here are the key drivers that move the needle:

Recurring Revenue: This is the holy grail. A practice where 40% of revenue comes from a membership model (e.g., monthly facials, “Botox bank”) is far more valuable than one relying entirely on one-off procedures. Recurring revenue is predictable and less dependent on constant marketing. It dramatically de-risks the investment for a buyer.
Provider Mix and Scalability: A practice heavily dependent on a single founding dermatologist is a risk. A practice with a diversified team of dermatologists, PAs, NPs, and aestheticians, each operating profitably, is a scalable platform. The less the business relies on any one individual, the higher the multiple.
Retail Product Sales: A strong, high-margin retail component (private label skincare, curated products) diversifies revenue streams and demonstrates patient loyalty. If product sales make up 15-20% of revenue, that’s a significant value driver.
Geographic Concentration and Growth Plan: A practice with a dominant market share in a desirable geography, or one with a clear, executable plan to open satellite locations, will command a premium. Buyers are purchasing future growth, not just past performance.

The trap is optimizing for personal income instead of enterprise value. It feels good to take home every last dollar of profit. But reinvesting in systems, marketing, and team members that build recurring revenue and reduce owner-dependency is what builds a sellable, high-multiple asset. You have to decide if you’re running a job or building a business. The physician finance hub can help you model these scenarios, showing how different practice decisions impact your long-term net worth, not just this year’s tax bill.

Cost Segregation Studies: Supercharging Real Estate Depreciation

For many practice owners, the biggest asset outside of the practice itself is the real estate it occupies. If you own your medical office building, you are likely leaving a massive tax deduction on the table by using standard depreciation.

When you buy a commercial property, the IRS typically allows you to depreciate the value of the building (not the land) over a 39-year straight-line schedule. A $3.9M building would generate a $100,000 depreciation deduction each year. A cost segregation study shatters this model.

A “cost seg” study is an engineering-based analysis that identifies and reclassifies components of your building from long-life real property (39-year) into short-life personal property (5, 7, or 15-year). Think of things like specialty electrical wiring for lasers, custom cabinetry, carpeting, specific plumbing, and exterior landscaping. These items can be depreciated much, much faster.

Here’s how it works:

You hire a specialized engineering firm to perform the study.
They analyze blueprints and conduct a site visit to identify all the components that can be reclassified.
The study might determine that 25% of your $3.9M building cost—$975,000—can be reclassified into 5-year and 15-year property.

The result is a monumental acceleration of your depreciation deductions. Instead of $100,000 per year, you might get a deduction of several hundred thousand dollars in the early years of ownership. Especially with “bonus depreciation” rules (which have allowed for 100% first-year write-offs in recent years, though this is phasing down), you could potentially generate a paper loss that wipes out a huge portion of your practice income.

The planning trap is simply not knowing this exists. Your regular CPA may not be an expert in this niche area. The cost of the study (typically a few thousand dollars) is almost always dwarfed by the immediate tax savings. For physicians who own real estate, this is one of the most powerful and underutilized strategies available. You can use a real estate investing calculator to see how accelerated depreciation impacts your cash flow and returns.

Building a successful cash-pay practice requires a dual focus: delivering exceptional clinical care and mastering the financial engineering that creates real wealth. The strategies outlined here—from structuring a potential sale to optimizing your tax position through R&D credits and real estate—are the building blocks of a financially resilient career. These aren’t just abstract concepts; they are actionable levers you can pull to change your financial trajectory. If you’re ready to apply these principles to your own practice and financial plan, you can talk to GigHz about a cash practice to develop a tailored strategy.